Advertisement

Topics

Minerva Neurosciences Announces Completion Of Bridging Study To Select Improved Formulation Of MIN-101 For Use In Phase III Trial For The Treatment Of Negative Symptoms In Patients With Schizophrenia

20:00 EDT 21 Jun 2017 | BioSpace

  Life Sciences Jobs   ...

Original Article: Minerva Neurosciences Announces Completion Of Bridging Study To Select Improved Formulation Of MIN-101 For Use In Phase III Trial For The Treatment Of Negative Symptoms In Patients With Schizophrenia

NEXT ARTICLE

More From BioPortfolio on "Minerva Neurosciences Announces Completion Of Bridging Study To Select Improved Formulation Of MIN-101 For Use In Phase III Trial For The Treatment Of Negative Symptoms In Patients With Schizophrenia"

Advertisement
Quick Search
Advertisement
Advertisement